{"id":164533,"date":"2026-07-31T18:55:11","date_gmt":"2026-07-31T18:55:11","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/164533\/"},"modified":"2026-07-31T18:55:11","modified_gmt":"2026-07-31T18:55:11","slug":"prvni-klinicke-testovani-nove-lecby-izraelsti-vedci-pokrocili-v-boji-s-rakovinou-slinivky","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/164533\/","title":{"rendered":"Prvn\u00ed klinick\u00e9 testov\u00e1n\u00ed nov\u00e9 l\u00e9\u010dby. Izrael\u0161t\u00ed v\u011bdci pokro\u010dili v\u00a0boji s\u00a0rakovinou slinivky"},"content":{"rendered":"

Studie bude hodnotit p\u0159\u00edpravek SIL204\u00a0vyvinut\u00fd izraelskou biotechnologickou spole\u010dnost\u00ed Silexion Therapeutics, kter\u00fd vyu\u017e\u00edv\u00e1 mal\u00e9 interferuj\u00edc\u00ed molekuly RNA (siRNA) k\u00a0potla\u010den\u00ed exprese mutovan\u00fdch gen\u016f KRAS uvnit\u0159 n\u00e1dorov\u00fdch bun\u011bk.<\/p>\n

Mutace genu KRAS se vyskytuj\u00ed asi u\u00a090\u00a0procent pacient\u016f s\u00a0karcinomem pankreatu a\u00a0jsou pova\u017eov\u00e1ny za jeden z\u00a0hlavn\u00edch mechanism\u016f podporuj\u00edc\u00edch r\u016fst n\u00e1doru a\u00a0\u0161\u00ed\u0159en\u00ed nemoci.<\/p>\n

V\u00fdvoj l\u00e9\u010debn\u00fdch terapi\u00ed schopn\u00fdch c\u00edlen\u011b zas\u00e1hnout gen KRAS se v\u00a0minulosti uk\u00e1zal jako mimo\u0159\u00e1dn\u011b obt\u00ed\u017en\u00fd, jak p\u0159ipomn\u011bl server The Jerusalem Post<\/a>, kter\u00fd na novou klinickou studii tento t\u00fdden ve \u010dtvrtek upozornil.<\/p>\n

<\/a><\/p>\n

P\u0159\u00edpravek SIL204\u00a0se m\u00e1 v\u00a0r\u00e1mci studie pod\u00e1vat p\u0159\u00edmo do n\u00e1doru a\u00a0kombinovat se standardn\u00ed syst\u00e9movou l\u00e9\u010dbou. V\u011bdci budou zkoumat, zda uml\u010den\u00ed mutovan\u00e9ho genu KRAS dok\u00e1\u017ee potla\u010dit r\u016fst n\u00e1doru u\u00a0pacient\u016f s\u00a0lok\u00e1ln\u011b pokro\u010dilou rakovinou slinivky b\u0159i\u0161n\u00ed, kterou nelze chirurgicky odstranit.<\/p>\n

Zat\u00edm 18\u00a0pacient\u016f<\/p>\n

Po\u010d\u00e1te\u010dn\u00ed f\u00e1ze studie zahrne 18\u00a0pacient\u016f a\u00a0bude se zam\u011b\u0159ovat p\u0159edev\u0161\u00edm na bezpe\u010dnost l\u00e9\u010dby. Pozd\u011bji se o\u010dek\u00e1v\u00e1 roz\u0161\u00ed\u0159en\u00ed studie do dal\u0161\u00edch zdravotnick\u00fdch center v\u00a0Izraeli, N\u011bmecku a\u00a0dal\u0161\u00edch zem\u00edch, p\u0159i\u010dem\u017e celkov\u00fd po\u010det za\u0159azen\u00fdch pacient\u016f by mohl dos\u00e1hnout 166.<\/p>\n

\u201eL\u00e9\u010dba rakoviny slinivky b\u0159i\u0161n\u00ed proch\u00e1z\u00ed v\u00fdznamnou prom\u011bnou. Jsme hrd\u00ed na to, \u017ee jsme prvn\u00edm centrem na sv\u011bt\u011b, kter\u00e9 vede tento v\u00a0Izraeli vyvinut\u00fd p\u0159\u00edstup kombinuj\u00edc\u00ed p\u0159\u00edm\u00e9 nitron\u00e1dorov\u00e9 pod\u00e1n\u00ed zkouman\u00e9 l\u00e9\u010dby se syst\u00e9movou terapi\u00ed u\u00a0pacient\u016f s\u00a0lok\u00e1ln\u011b pokro\u010dil\u00fdm, chirurgicky neodstraniteln\u00fdm onemocn\u011bn\u00edm,\u201c uvedla hlavn\u00ed \u0159e\u0161itelka studie Ravit Geva, \u0159editelka Onkologick\u00e9ho institutu a\u00a0Centra gastrointestin\u00e1ln\u00ed onkologie ve zm\u00edn\u011bn\u00e9 telavivsk\u00e9 nemocnici.<\/p>\n

Podle gener\u00e1ln\u00edho \u0159editele firmy Silexion Ilana Hadara pom\u016f\u017ee studie zjistit, zda by komplexn\u00ed a\u00a0c\u00edlen\u00e9 uml\u010den\u00ed genu KRAS mohlo v\u00a0budoucnu p\u0159edstavovat dal\u0161\u00ed mo\u017enost l\u00e9\u010dby pacient\u016f s\u00a0rakovinou slinivky b\u0159i\u0161n\u00ed. Samotn\u00e1 l\u00e9\u010dba je zat\u00edm st\u00e1le ve f\u00e1zi klinick\u00e9ho v\u00fdzkumu a\u00a0jej\u00ed bezpe\u010dnost ani \u00fa\u010dinnost dosud nebyly v\u00a0r\u00e1mci klinick\u00e9 studie prok\u00e1z\u00e1ny.<\/p>\n

O zah\u00e1jen\u00ed t\u00e9to studie p\u0159\u00edpravku SIL204\u00a0v\u00a0Tel Aviv Sourasky Medical Center referoval i\u00a0web Yahoo Finance<\/a> s\u00a0t\u00edm, \u017ee dan\u00fd miln\u00edk p\u0159edstavuje za\u010d\u00e1tek p\u0159echodu programu spole\u010dnosti Silexion z\u00a0f\u00e1ze p\u0159\u00edprav do aktivn\u00ed f\u00e1ze klinick\u00e9ho hodnocen\u00ed, kter\u00e1 za\u010d\u00edn\u00e1 n\u00e1borem a\u00a0screeningem pacient\u016f. Navazuje to na ud\u011blen\u00e1 povolen\u00ed od izraelsk\u00e9ho ministerstva zdravotnictv\u00ed a\u00a0n\u011bmeck\u00e9ho Spolkov\u00e9ho institutu pro l\u00e9\u010diva a\u00a0zdravotnick\u00e9 prost\u0159edky.<\/p>\n

Izraelsk\u00e1 studie p\u0159ich\u00e1z\u00ed v\u00a0dob\u011b, kdy se v\u00fdzkum l\u00e9\u010dby rakoviny slinivky zrychluje. Nap\u0159\u00edklad v\u00a0USA z\u00edskal experiment\u00e1ln\u00ed p\u0159\u00edpravek daraxonrasib<\/a> mimo\u0159\u00e1dn\u00e9 povolen\u00ed pro pou\u017eit\u00ed u\u00a0prvn\u00edch pacient\u016f je\u0161t\u011b p\u0159ed definitivn\u00edm schv\u00e1len\u00edm. Na rozd\u00edl od izraelsk\u00e9ho SIL204, kter\u00fd vyu\u017e\u00edv\u00e1 molekuly siRNA k\u00a0uml\u010den\u00ed mutovan\u00e9ho genu KRAS, jde o\u00a0malou molekulu blokuj\u00edc\u00ed aktivitu proteinu KRAS. Oba p\u0159\u00edstupy ale spojuje snaha c\u00edlen\u011b zas\u00e1hnout mutaci KRAS, kter\u00e1 je p\u0159\u00edtomna u\u00a0v\u011bt\u0161iny p\u0159\u00edpad\u016f karcinomu pankreatu.<\/p>\n

<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Studie bude hodnotit p\u0159\u00edpravek SIL204\u00a0vyvinut\u00fd izraelskou biotechnologickou spole\u010dnost\u00ed Silexion Therapeutics, kter\u00fd vyu\u017e\u00edv\u00e1 mal\u00e9 interferuj\u00edc\u00ed molekuly RNA (siRNA) k\u00a0potla\u010den\u00ed…\n","protected":false},"author":2,"featured_media":164534,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[11],"tags":[638,1616,2813,375,2811,25600,54,113,77,53,52],"class_list":["post-164533","post","type-post","status-publish","format-standard","has-post-thumbnail","category-svet","tag-izrael","tag-klinicke-studie","tag-lecba","tag-nemecko","tag-rakovina","tag-rakovina-slinivky-brisni","tag-svet","tag-usa","tag-veda","tag-world","tag-world-news"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/117016115988038855","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/164533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=164533"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/164533\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/164534"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=164533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=164533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=164533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}